Last reviewed · How we verify
NCT03877627
The Clinical Significance of Sentinel Lymph Node Imaging Combined With Imaging Examination in Pelvic and Peritoneal Lymphadenectomy for Endometrial Carcinoma
NA trial testing Pelvic and Peritoneal Lymphadenectomy in Endometrial Carcinoma in 60 participants. Status unknown.
15 March 2023
Quick facts
| Lead sponsor | Second Affiliated Hospital of Wenzhou Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 1 April 2022 |
| Primary completion | 15 March 2023 |
| Estimated completion | 1 April 2023 |
Drugs / interventions tested
- Pelvic and Peritoneal Lymphadenectomy
Conditions studied
- Endometrial Carcinoma — all drugs for Endometrial Carcinoma →
- Lymphadenectomy — all drugs for Lymphadenectomy →
Sponsor
Second Affiliated Hospital of Wenzhou Medical University
Who can join
Adults 10 to 90, female only, with Endometrial Carcinoma or Lymphadenectomy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this prospective cohort study is to explore the clinical significance of sentinel lymph node imaging combined imaging examination evaluation in pelvic and peritoneal lymphadenectomy for endometrial carcinoma management.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03877627
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Carcinoma
Currently open trials in the same condition.
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07062016 — Molecular and ctDNA Characterization of High-Risk Endometrial Cancer · recruiting
- NCT07407959 — Screening and Staging of Benign vs Malignant Pelvic Abnormalities · recruiting
- NCT06855706 — An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV · NA · recruiting
- NCT06632431 — Clinicopathological Analysis of Endometrial Carcinoma in the View of Old and New International Federation of Gynecology · recruiting
Other Second Affiliated Hospital of Wenzhou Medical University trials
Trials by the same sponsor.
- NCT07466511 — Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis · NA · not yet recruiting
- NCT07530848 — Perioperative Pharmacokinetics of Anesthetic Drugs and Complications in Overweight and Obese Patients · not yet recruiting
- NCT07346443 — Mechanism Study of G Protein-coupled Receptor 81 in Multiple Organ Dysfunction of Heat Stroke · not yet recruiting
- NCT07353970 — Mechanisms of Prognostic Regulation andPrecision Phenotype Ldentification in Severe Infections Driven by SpecializedPro- · not yet recruiting
- NCT07332793 — Mechanisms of Precise Immune Cell Phenotyping and Prognostic Prediction in Severe Infection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03877627 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital of Wenzhou Medical University
- Last refreshed: 29 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03877627.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing